Business Wire

MAXON Cinema 4D MoGraph Toolset Honored with Academy Certificate for Scientific and Technical Achievement

Share

MAXON, the industry-leading developer of professional 3D modeling, painting, animation and rendering solutions, is pleased to announce the MoGraph module in the company’s cornerstone 3D professional application, Cinema 4D, was recognized by the Academy of Motion Picture Arts and Sciences with a Technical Achievement Award (Academy Certificate). Principal architect and award recipient, Per-Anders Edwards of MAXON, accepted the award at the annual Sci-Tech Awards Presentation held February 9, at the Beverly Wilshire in Beverly Hills.

The Academy’s Scientific and Technical Awards honor the men, women and companies whose discoveries and innovations have contributed in significant and lasting ways to motion pictures. An innovator within the computer graphics field, Edwards is currently software architect and lead developer and designer at MAXON for the legendary motion graphics workflow in Cinema 4D. The Academy recognized Edwards with the Sci-Tech Award for his contribution to the initial design and development of the MoGraph toolset that “…provides a fast, non-destructive and intuitive workflow for motion designers to create animated 3D graphics, as used for title design and fictional user interfaces in motion pictures.”

“Receiving the Sci-Tech Award is a phenomenal honor,” said Edwards. “I believe the success of the MoGraph toolset can be attributed to my original desire to satisfy my practical needs and calling upon my experience as a motion graphics artist. This happened because of Maxon’s unwavering support, belief and trust in that vision. Sometimes my concepts were out of the box, but they were always firmly planted in the landscape of Cinema 4D in a way that meant it could not have been developed anywhere else.”

“This award represents the hard work of Maxon’s unbelievably talented developers and dedicated team,” added Edwards. “Without this family, it would not have reached this stature. Though ultimately, MoGraph’s continued enhancement and success should really be attributed to the raw talent and passion of our community, who continually surprise me and push its boundaries.”

Since MAXON introduced MoGraph in 2006, it continues to be cited by VFX and animation professionals worldwide for its essential role in the demanding, fast-paced 3D animation and modeling concepts to production processes on some of the most highly acclaimed movies of all time. Blade Runner 2049, winner of the 2018 Oscar® for Achievement in Visual Effects, and several of this year’s Oscar Visual Effects nominees: The Avengers: Infinity War, Ready Player One, and Black Panther, nominated for Best Picture, are just a few of the numerous film titles that have relied on MoGraph’s renowned reliability and fast, intuitive workflow.

According to MAXON Chief Executive Officer, David McGavran, innovation continues to be a hallmark that embodies the company’s software development philosophy.

"MAXON is thrilled the Academy has recognized our MoGraph toolset with a Sci-Tech Award for technical contributions that help artists solve today’s complex film visual effects workflow challenges,” said McGavran. “We congratulate and thank Per-Anders for his ground-breaking work on the MoGraph toolset for Cinema 4D, while acknowledging the accomplishments of the entire company that contributed to this outstanding acknowledgment.”

Image links are available at:
http://bit.ly/2RTkQjp
http://photos.presslist.oscars.org/

About MAXON

Headquartered in Friedrichsdorf, Germany, MAXON Computer is a developer of professional 3D modeling, painting, animation and rendering solutions. Its award-winning Cinema 4D and BodyPaint 3D software products have been used extensively to help create everything from stunning visual effects in top feature films, TV shows and commercials, cutting-edge game cinematics for AAA games, as well for medical illustration, architectural and industrial design applications. MAXON has offices in Germany, USA, United Kingdom, Canada, France, Japan and Singapore. MAXON products are available directly from the web site and its worldwide distribution channel. MAXON is part of the Nemetschek Group.

Additional information on MAXON can be obtained as follows:
Website: http://www.maxon.net/
Cineversity: http://www.cineversity.com/
Facebook: https://www.facebook.com/maxon3d
Twitter: https://twitter.com/maxon3D
YouTube: https://www.youtube.com/user/MaxonC4D
LinkedIn: https://www.linkedin.com/company/791366
Instagram: https://www.instagram.com/maxonc4d/

All trademarks contained herein are the property of their respective owners.

Contact information

Media Contact
Vicky Gray-Clark / Ambient PR
408-318-1980 / vicky@ambientpr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

c-LEcta: Successful Product Business in the First Half of 201922.8.2019 11:06:00 EESTPress release

c-LEcta, a globally active biotechnology company with technology leadership in enzyme engineering and bioprocess development, successfully expanded its product business in the first half of 2019. Besides sales increases across the entire portfolio, the company was granted many new patents. While the patent portfolio still comprised 59 granted patents at the end of the first half of 2018, the Leipzig-based company now holds more than 80 patents. c-LEcta’s DENARASE®, which is used for the necessary removal of nucleic acids from biopharmaceutical products, performed particularly well. DENARASE® is the most efficient technology on the market for meeting the stringent regulatory requirements for biopharmaceutical products. Sales of this product increased by 164% year-on-year in the first half of 2019. The other products in c-LEcta’s portfolio also performed very well and contributed to the positive development of the product business. c-LEcta now markets its self-developed products in 25 co

MobileIron Named a Leader Again in the Second Gartner Magic Quadrant for Unified Endpoint Management Tools22.8.2019 10:00:00 EESTPress release

MobileIron (NASDAQ:MOBL), the company that introduced the industry’s first mobile-centric, zero trust platform for the enterprise, today announced that it has been positioned as a Leader for the second consecutive year in the Gartner Magic Quadrant for Unified Endpoint Management Tools. The report evaluated 11 vendors based on completeness of vision and ability to execute. “To us, it’s an honor to be recognized once again as a Leader in Gartner’s Magic Quadrant for Unified Endpoint Management Tools,” said Simon Biddiscombe, CEO, MobileIron. “We have continued to innovate and expand upon our UEM platform to keep up with the demands of today’s digital businesses. Earlier this year, we introduced a revolutionary zero sign-on experience to eliminate passwords and make the world’s most ubiquitous product – the mobile device – your ID and secure access to the enterprise built on our leadership foundation in UEM. Mobile and cloud technologies have driven a dramatic change in organizations acr

Miracor Medical Granted FDA Breakthrough Device Designation for the PiCSO Impulse System22.8.2019 09:00:00 EESTPress release

Miracor Medical SA (Miracor Medical) has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its PiCSO® Impulse System for treatment of STEMI patients. The FDA Breakthrough Device designation is intended to speed time to market for treatments of life-threatening or irreversibly debilitating diseases or conditions and recognizes the novelty of the PiCSO Impulse System and its potential to benefit patients with anterior STEMI heart attacks. The Centers for Medicare & Medicaid Services (CMS) also recently acknowledged the importance of this designation by establishing an alternative reimbursement pathway for products that receive FDA marketing authorization and held the Breakthrough Designation. PiCSO therapy is provided by interventional cardiologists during PCI (Percutaneous Coronary Intervention) in patients experiencing ST-elevated myocardial infarction (STEMI). The PiCSO Impulse System clears the coronary microcirculation by intermittently

Mori Building Unveils Massive Urban Regeneration Project in Central Tokyo22.8.2019 07:00:00 EESTPress release

Mori Building Co., Ltd., a leading urban landscape developer, has begun construction on its “Toranomon-Azabudai District Category 1 Urban Redevelopment Project,” a massive urban regeneration project aimed at revitalizing a large area of central Tokyo. A groundbreaking ceremony was held on August 5 and project completion is scheduled for the end of March 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190821005445/en/ Image of Office Lobby (Graphic: Business Wire) The core concept of the Toranomon-Azabudai Project is that of a “Modern Urban Village,” a unique neighborhood that will combine the sophistication of a megalopolis with the intimacy of a small village in the heart of Tokyo. It will cover an area of approximately 8.1 hectares, similar to that of New York’s Rockefeller Center, and will feature extensive greenery totaling 24,000 m2 including a 6,000 m2 central square. Total floor area will be 860,400 m2, including

Mundipharma Announces the Licence Extension Submission for Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin) to the European Medicines Agency22.8.2019 02:01:00 EESTPress release

STRICTLY FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY As the European distributor of Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin), Mundipharma welcomes the news that the European Medicines Agency (EMA) has accepted the licence extension submission for these two medicines to treat stage 2 or stage 3 chronic kidney disease (CKD) and albuminuria as an adjunct to standard of care in adults with type 2 diabetes mellitus (T2DM). The submission is based on the results from the landmark Phase III CREDENCE study1 which evaluated the efficacy and safety of canagliflozin versus placebo in this high-risk patient population when used in addition to standard of care. “Chronic kidney disease is a serious complication of type 2 diabetes, which can increase patients’ risk of developing end-stage renal disease and may reduce their life expectancy by several years.” said Dr Vinicius Gomes de Lima, European Medical Affairs Lead, Mundipharma. “If approved, this licence

Triton Digital Releases Webcast Metrics Rankings for the Top Digital Audio Properties for April 201921.8.2019 23:00:00 EESTPress release

Triton Digital®, the global technology and services leader to the digital audio and podcast industry, released today its monthly Webcast Metrics® rankers for April 2019. The global rankers, in addition to the U.S., LATAM, and EMEA regional rankers provide insight into the top-performing streaming audio stations and networks around the world for the month of April. The full results of the Global & Regional Rankers for April 2019 can be found here: https://www.tritondigital.com/resources/monthly-rankers/rankers-archive The Webcast Metrics streaming measurement service is the industry standard for online audio consumption data. It provides credible, validated data that enables audio publishers around the world to analyze the consumption of their audio content by daypart, device type, geography, distribution platform, and more. About Triton Digital Triton Digital® is the global technology and services leader to the digital audio and podcast industry. Operating in more than 40 countries, Tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom